SCHEMBL17350656

SCHEMBL17350656

CCCCCCCCCCCCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.65
KDM4E B2RXH2 9/20 0.63
HPGD P15428 4/20 0.63
ALDH1A1 P00352 4/20 0.63
HSD17B10 Q99714 2/20 0.63
POLB P06746 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
PRKD3 O94806 1/20 0.63
ALOX15 P16050 1/20 0.63
OPRM1 P35372 1/20 0.63
CLK2 P49760 1/20 0.63
CLK4 Q9HAZ1 1/20 0.63
LMNA P02545 2/20 0.60
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
NPSR1 Q6W5P4 1/20 0.56
CYP2C19 P33261 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
ATM Q13315 1/20 0.55
GSK3B P49841 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17350795 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350680 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350608 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350483 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350507 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350640 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350588 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350661 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350440 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10
SCHEMBL17350304 1.00 KCNH2 (0.65) KCNH2KDM4EHPGDALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10087165-B2 Fluoroquinolones and use thereof to treat bacterial infections SORBONNE UNIVERSITE (FR) 2018-10-02 US claimed
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-05-25 US claimed
EP-3157911-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS Université Pierre et Marie Curie - Paris 6 (UPMC) (FR) 2017-04-26 EP claimed
EP-2957561-A1 Novel fluoroquinolones and use thereof to treat bacterial infections Université Paris 6 Pierre et Marie Curie UPMC (FR) 2015-12-23 EP claimed
WO-2015193454-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2015-12-23 WO claimed
US-10087165-B2 Fluoroquinolones and use thereof to treat bacterial infections SORBONNE UNIVERSITE (FR) 2018-10-02 US disclosed
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-05-25 US disclosed
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-05-25 US disclosed
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-05-25 US disclosed
EP-3157911-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS Université Pierre et Marie Curie - Paris 6 (UPMC) (FR) 2017-04-26 EP disclosed
EP-2957561-A1 Novel fluoroquinolones and use thereof to treat bacterial infections Université Paris 6 Pierre et Marie Curie UPMC (FR) 2015-12-23 EP disclosed
EP-2957561-A1 Novel fluoroquinolones and use thereof to treat bacterial infections Université Paris 6 Pierre et Marie Curie UPMC (FR) 2015-12-23 EP disclosed
WO-2015193454-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2015-12-23 WO disclosed
WO-2015193454-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2015-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10087165-B2 Fluoroquinolones and use thereof to treat bacterial infections CFTR, NQO2, FPR1 KCNH2 4262/4885KDM4E 3086/4885HPGD 755/4885
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS CFTR, IRF3, FPR1 KCNH2 4615/4885KDM4E 3242/4885HPGD 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.